KR100879712B1 - 탁산과 사이클린-의존성 키나제 억제제와의 병용제제 - Google Patents

탁산과 사이클린-의존성 키나제 억제제와의 병용제제 Download PDF

Info

Publication number
KR100879712B1
KR100879712B1 KR1020037012338A KR20037012338A KR100879712B1 KR 100879712 B1 KR100879712 B1 KR 100879712B1 KR 1020037012338 A KR1020037012338 A KR 1020037012338A KR 20037012338 A KR20037012338 A KR 20037012338A KR 100879712 B1 KR100879712 B1 KR 100879712B1
Authority
KR
South Korea
Prior art keywords
taxotere
combination
days
administered
dependent kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037012338A
Other languages
English (en)
Korean (ko)
Other versions
KR20030086318A (ko
Inventor
비쎄리마리-크리스틴
Original Assignee
아방티 파르마 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아방티 파르마 소시에테 아노님 filed Critical 아방티 파르마 소시에테 아노님
Publication of KR20030086318A publication Critical patent/KR20030086318A/ko
Application granted granted Critical
Publication of KR100879712B1 publication Critical patent/KR100879712B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037012338A 2001-03-23 2002-03-22 탁산과 사이클린-의존성 키나제 억제제와의 병용제제 Expired - Fee Related KR100879712B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US60/277,948 2001-03-23
US30269201P 2001-07-05 2001-07-05
US60/302,692 2001-07-05
US33491601P 2001-12-04 2001-12-04
US60/334,916 2001-12-04
PCT/EP2002/004083 WO2002076484A2 (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kinase inhibitor

Publications (2)

Publication Number Publication Date
KR20030086318A KR20030086318A (ko) 2003-11-07
KR100879712B1 true KR100879712B1 (ko) 2009-01-22

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037012338A Expired - Fee Related KR100879712B1 (ko) 2001-03-23 2002-03-22 탁산과 사이클린-의존성 키나제 억제제와의 병용제제

Country Status (33)

Country Link
US (2) US20020182204A1 (enExample)
EP (1) EP1372652B1 (enExample)
JP (1) JP2004521140A (enExample)
KR (1) KR100879712B1 (enExample)
CN (1) CN1498107A (enExample)
AR (1) AR034222A1 (enExample)
AT (1) ATE395917T1 (enExample)
AU (1) AU2002312815B2 (enExample)
BR (1) BR0208221A (enExample)
CA (1) CA2441441C (enExample)
CY (1) CY1110449T1 (enExample)
CZ (1) CZ301423B6 (enExample)
DE (1) DE60226710D1 (enExample)
DK (1) DK1372652T3 (enExample)
EA (1) EA007815B1 (enExample)
ES (1) ES2305253T3 (enExample)
HR (1) HRPK20030766B3 (enExample)
HU (1) HU229258B1 (enExample)
IL (2) IL158058A0 (enExample)
ME (1) MEP16408A (enExample)
MX (1) MXPA03007743A (enExample)
NO (1) NO332441B1 (enExample)
NZ (1) NZ527655A (enExample)
PE (1) PE20020907A1 (enExample)
PL (1) PL206118B1 (enExample)
PT (1) PT1372652E (enExample)
RS (1) RS50681B (enExample)
SI (1) SI1372652T1 (enExample)
SK (1) SK287481B6 (enExample)
TW (1) TWI355935B (enExample)
UY (1) UY27220A1 (enExample)
WO (1) WO2002076484A2 (enExample)
ZA (1) ZA200307381B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003217982A1 (en) * 2002-03-06 2003-09-22 The Medical Research And Education Trust Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
AU2003287081A1 (en) * 2002-10-16 2004-05-04 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
EP1558242B1 (en) * 2002-11-06 2008-12-24 Cyclacel Limited Combination comprising docetaxel and a cdk inhibitor
ES2390237T3 (es) * 2006-02-10 2012-11-07 Nerviano Medical Sciences S.R.L. Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico
BR112013012313A2 (pt) * 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
ME03589B (me) 2011-04-01 2020-07-20 Astrazeneca Ab Terapeutski tretman
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030174A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997030174A1 (en) * 1996-02-20 1997-08-21 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
논문 (Clinical Cancer Research. 1999)*
논문 (Pharmacotherapy. 1997)*

Also Published As

Publication number Publication date
NO20034124L (no) 2003-09-16
TWI355935B (en) 2012-01-11
UY27220A1 (es) 2002-09-30
PT1372652E (pt) 2008-07-24
SK11692003A3 (sk) 2004-03-02
ATE395917T1 (de) 2008-06-15
DE60226710D1 (de) 2008-07-03
CY1110449T1 (el) 2015-04-29
HUP0303589A2 (hu) 2004-03-01
WO2002076484A3 (en) 2003-01-03
MXPA03007743A (es) 2004-11-12
BR0208221A (pt) 2004-03-02
EA007815B1 (ru) 2007-02-27
EP1372652B1 (en) 2008-05-21
IL158058A (en) 2010-02-17
NZ527655A (en) 2006-03-31
RS50681B (sr) 2010-06-30
ZA200307381B (en) 2005-03-30
CA2441441C (en) 2009-05-26
KR20030086318A (ko) 2003-11-07
JP2004521140A (ja) 2004-07-15
PL206118B1 (pl) 2010-07-30
HUP0303589A3 (en) 2007-05-02
US20060128640A1 (en) 2006-06-15
CN1498107A (zh) 2004-05-19
SI1372652T1 (sl) 2008-10-31
YU69503A (sh) 2006-08-17
US20020182204A1 (en) 2002-12-05
PL367702A1 (en) 2005-03-07
CA2441441A1 (en) 2002-10-03
EA200301053A1 (ru) 2004-02-26
ES2305253T3 (es) 2008-11-01
SK287481B6 (sk) 2010-11-08
DK1372652T3 (da) 2008-09-22
CZ20032551A3 (en) 2004-07-14
HRPK20030766B3 (en) 2006-11-30
NO20034124D0 (no) 2003-09-16
PE20020907A1 (es) 2002-12-19
NO332441B1 (no) 2012-09-17
HRP20030766A2 (en) 2005-06-30
EP1372652A2 (en) 2004-01-02
HU229258B1 (en) 2013-10-28
AU2002312815B2 (en) 2006-08-24
CZ301423B6 (cs) 2010-02-24
MEP16408A (en) 2010-10-10
AR034222A1 (es) 2004-02-04
WO2002076484A2 (en) 2002-10-03
IL158058A0 (en) 2004-03-28

Similar Documents

Publication Publication Date Title
KR100334051B1 (ko) 탁산유도체를함유하는항종양조성물
EP2320903B1 (en) THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
EP2435041B1 (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
CN1935134B (zh) 包含考布他汀和抗癌剂的组合
JP2004536790A (ja) タキサン誘導体を含有する抗腫瘍組成物
BG66113B1 (bg) Комбиниран химиотерапевтичен състав
JP2009536956A (ja) 抗癌治療法
KR20030086318A (ko) 탁산과 사이클린-의존성 키나제 억제제와의 배합물
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
KR100742524B1 (ko) 캄프토테신과 스틸벤 유도체를 포함하는 암 치료용 약제학적 병용제제
Ghaemmaghami et al. New agents in the treatment of small cell lung cancer
AU2002216029A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
HK1060843A1 (en) Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases
HK1060843B (en) Combination of an epothilone analog and chemotherapeutic agents for the treatment of proliferative diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20111223

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20121226

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140115

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140115

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000